Similar gene expression profiles of sporadic, PGL2-, and SDHD-linked paragangliomas suggest a common pathway to tumorigenesis

Table 1 Clinicopathological characteristics and mutation status

sample	tumor	location	family history	mutation	sex	age at onset (yrs)	multiple paragangliomas
1	PGL04	CBT	PGL2	-	f	28	yes
2	PGL01	CBT	PGL2	-	f	28	yes
3	PGL02	CBT	PGL2	-	m	37	yes
4	PGL19	CBT	PGL2	-	f	32	yes
5	PGL05	CBT	SDHD	D92Y	m	43	yes
6	PGL06	CBT	SDHD	D92Y	m	47	yes
7	PGL13	CBT	SDHD	D92Y	f	29	yes
8	PGL14	CBT	SDHD	D92Y	f	45	no
9	PGL16	CBT	SDHD	D92Y	f	47	yes
10	PGL17	CBT	SDHD	D92Y	f	74	no
11	PGL10	CBT	SPOR	-	f	44	no
13	PGL12	CBT	SPOR	-	f	49	no
14	PGL15	CBT	SPOR	-	f	38	no
15	PGL23	CBT	SPOR	-	f	70	no
16	PGL20	CBT	SPOR	-	m	27	no

CBT = carotid body tumor; PGL2 = positive family history for PGL2-linked paragangliomas; SDHD = positive family history for SDHD-linked paragangliomas; SPOR = sporadic sample, negative family history of paraganglioma or phaeochromocytoma and no mutation in the SDHB, SDHC or SDHD gene; D92Y = Asp92Tyr, a Dutch founder mutation in the SDHD gene; m = male patient, f = female patient.

ISSN: 1755-8794